Injections, Creams, Pellets, Pills, Troches: Which Hormone Delivery Method Is Actually Right for You?

You've finally decided. After months, maybe years, of feeling like a worn-down version of yourself, you're ready to do something about your hormones. And then you start researching, and you hit a wall of options. Injections. Creams. Pellets. Pills. Patches. Troches that dissolve under your tongue. Everyone you talk to has a strong opinion, and somehow every opinion is different.

Here's the part nobody tells you: most of those people aren't wrong. They've just confused what worked for them with what's best for everyone. Those are not the same thing.

The best delivery method isn't a universal answer. It's the one that fits your physiology, your bloodstream, your lifestyle, and your goals.

The delivery method matters more than most people realize, because it determines something the label never quite explains: how the hormone actually behaves once it's in your body. Two people can take the same hormone and have completely different experiences, simply because of how it was delivered. Here's why.

Why Delivery Method Changes Everything

When we talk about hormone delivery, we're really talking about three things. How fast the hormone enters your bloodstream. How steady the level stays. And how predictable that pattern is from person to person.

A hormone that enters quickly and clears quickly produces peaks and valleys. A hormone that enters slowly and steadily produces a flat, stable line. Neither is automatically better. Some people feel their best on a steady line. Others tolerate a gentle rhythm of peaks and troughs just fine, since that's closer to how the body produces hormones on its own.

The trouble starts when a delivery method produces a pattern your body doesn't tolerate well: a peak too high, a trough too low, or a level that swings in a way you feel. That's when people feel off even though they're technically on therapy.

The Three Variables That Actually Matter

Absorption kinetics is how quickly the hormone gets into your system. Half-life is how long it stays before your body clears half of it. Blood-level stability is how flat or how variable the resulting curve is over days or weeks.

Every delivery method is just a different combination of those three variables. Once you understand that, the "which is best" debate mostly dissolves. The better question isn't which method is best. It's which curve fits you.

Testosterone: The Most Debated Delivery Decision

Testosterone has the most delivery options and the loudest opinions, partly because the differences between routes are genuinely large. A comprehensive pharmacokinetic comparison across formulations found that the timing, magnitude, and duration of peak-to-trough testosterone swings vary substantially by route, and that none of the standard formulations actually reproduce the body's natural daily rhythm, where testosterone runs higher in the morning and lower at night.

Intramuscular injections, typically given weekly or every two weeks, create a real peak shortly after the injection and a gradual decline until the next dose. Some people feel great on the peak and flat by the end of the interval. Others feel the swing.

Subcutaneous injections, often given more frequently in smaller doses, tend to produce a gentler, more even curve than intramuscular dosing. A review from the Brigham and Women's men's health research program describes subcutaneous dosing as a safe, practical option with steadier levels between injections than the traditional intramuscular approach, largely because the more frequent, smaller doses smooth out the peak-and-trough pattern.

Topical creams and gels, applied daily, aim for a steadier state but depend heavily on absorption, which varies by skin site. A pharmacokinetic study of testosterone cream applied to scrotal skin found meaningfully faster and higher absorption at that site compared with standard application areas, which is why site matters as much as formulation.

Pellets, inserted under the skin every three to six months, offer real convenience: no daily dosing, no injections to remember. The tradeoff is that once they're in, the dose can't be adjusted. If the level runs too high early on, or too low near the end of the interval, there's no way to correct it until the next insertion.

Troches, which dissolve under the tongue, and nasal gels are less commonly used for testosterone specifically, mainly because absorption through oral mucosa tends to be less consistent from person to person. They're real options some patients specifically ask about, and worth understanding honestly rather than dismissing outright: they can work, but the predictability tends to be lower than injectable or topical routes.

Estradiol and Progesterone: The Same Logic, Different Curves

The delivery conversation isn't unique to testosterone. Estradiol and progesterone follow the same principle: how you take the hormone shapes how it behaves.

Oral estradiol and transdermal estradiol produce strikingly different curves. A pharmacokinetic study comparing a 2 mg oral tablet to a 50 microgram transdermal patch found that oral estradiol spikes to a peak within under an hour and falls off within a few hours, while the patch holds a much steadier, lower level with far less swing. Neither is inherently wrong. Someone who wants convenience and doesn't mind a daily rise and fall may do fine orally. Someone who wants a flatter, more consistent exposure may prefer the patch. Injectable estradiol esters exist as well, following the same peak-then-decline pattern as testosterone injections, just on a different timescale.

Progesterone tells a similar story. Oral micronized progesterone has long been the standard option, and it's well studied precisely because oral progesterone historically had a bioavailability problem: without micronization, very little of it survives the liver's first-pass metabolism intact. Micronization solved enough of that problem to make oral dosing clinically useful, though bioavailability still runs low compared with other routes, which is part of why oral progesterone tends to come with more of the sedating, sleep-related side effect than other forms. Vaginal administration bypasses much of that first-pass effect. A head-to-head pharmacokinetic comparison of two micronized progesterone formulations found that vaginal administration produced meaningfully different absorption and clearance patterns than oral administration of the same drug, underscoring that route, not just dose, drives the outcome. Injectable progesterone exists too, though it's used far less often outside specific clinical contexts, mainly because the other routes usually accomplish the same goal with less discomfort.

What This Looks Like in Practice

A patient in their late forties came in after two years of feeling flat: low energy, a noticeable dip in motivation, and workouts that used to leave them energized now leaving them wiped out for days. An outside provider had started them on a standard weekly intramuscular testosterone injection. The levels on paper looked reasonable, but the patient described feeling great for two or three days after each shot, then increasingly foggy and irritable as the week wore on.

That pattern is not a failure of testosterone therapy. It's a mismatch between the delivery curve and how that particular person's body responds to swings versus steady state. Switching to smaller, more frequent subcutaneous injections smoothed the curve considerably. Within about six weeks, the peak-trough swing the patient had been feeling was largely gone, and the improvement in mood and energy became far more consistent across the week rather than concentrated in the days right after dosing.

Which Route Actually Fits You

There's no universal answer here, and anyone who tells you there is one is selling a preference, not a physiologic fact. A few honest questions help narrow it down. Do you tolerate peaks and troughs well, or do you feel every fluctuation? Do you want the lowest-maintenance option, even if it means less ability to fine-tune once it's started? Are you comfortable with self-injection, or does that rule out an otherwise-reasonable option before you even start?

None of these questions have a wrong answer. They just point toward a different curve.

What to Expect and How Monitoring Works

Whatever route you start with, monitoring is what actually confirms it's working, rather than assuming it is. Initial follow-up labs typically happen around six to eight weeks after starting or changing a protocol, timed to when levels have stabilized for that particular delivery method. After that, monitoring every three to six months is standard once things look settled. This isn't a formality. It's how dose and delivery get fine-tuned to the individual instead of left on a generic starting protocol indefinitely.

Most people notice a shift in energy and mental clarity within four to eight weeks. Changes in body composition and sleep quality tend to take longer, often three to six months, to fully show up. If the first delivery method you try doesn't fit, that's useful information, not a failure. Switching routes is a normal part of finding the right fit, not a sign that hormone therapy itself isn't working for you.

Start with a Conversation

If you're trying to figure out which approach actually fits your body and your life, a free consultation is a reasonable next step. It's a conversation, not a commitment: a chance to ask your questions and understand your options before you decide anything. Because everyone's physiology is genuinely different, that individualized starting point is the whole point. Virtual consultations are available for patients in Texas and Arizona.

This article is for educational purposes only and does not constitute medical advice. It is not intended to diagnose, treat, or recommend any specific therapy, medication, dose, or delivery method. Hormone therapy carries risks and benefits that vary by individual, and some delivery methods or formulations discussed may be used off-label. Always consult a qualified physician before beginning any hormone therapy. Individual results vary.

References

1. Pastuszak AW, Gittelman M, Tursi JP, Jaffe JS, Schofield D, Miner MM. Pharmacokinetics of testosterone therapies in relation to diurnal variation of serum testosterone levels as men age. Andrology. 2022;10(2):209-222. PMID: 34510812

2. Figueiredo MG, Gagliano-Jucá T, Basaria S. Testosterone therapy with subcutaneous injections: a safe, practical, and reasonable option. J Clin Endocrinol Metab. 2022;107(3):614-626. PMID: 34698352

3. Iyer R, Mok SF, Savkovic S, Turner L, Fraser G, Desai R, Jayadev V, Conway AJ, Handelsman DJ. Pharmacokinetics of testosterone cream applied to scrotal skin. Andrology. 2017;5(4):725-731. PMID: 28334510

4. Setnikar I, Rovati LC, Vens-Cappell B, Hilgenstock C. Pharmacokinetics of estradiol and of estrone during repeated transdermal or oral administration of estradiol. Arzneimittelforschung. 1996;46(8):766-773. PMID: 9125276

5. Wang H, Liu M, Fu Q, Deng C. Pharmacokinetics of hard micronized progesterone capsules via vaginal or oral route compared with soft micronized capsules in healthy postmenopausal women: a randomized open-label clinical study. Drug Des Devel Ther. 2019;13:2475-2482. PMID: 31440031

6. Sitruk-Ware R, Bricaire C, De Lignières B, Yaneva H, Mauvais-Jarvis P. Oral micronized progesterone: bioavailability, pharmacokinetics, pharmacological and therapeutic implications. A review. Contraception. 1987;36(4):373-402. PMID: 3327648

7. Wallace IR, McKinley MC, Bell PM, Hunter SJ. Sex hormone binding globulin and insulin resistance. Clin Endocrinol (Oxf). 2013;78(3):321-329. PMID: 23121642

8. Laurent MR, Hammond GL, Blokland M, Jardí F, Antonio L, Dubois V, Khalil R, Sterk SS, Gielen E, Decallonne B, Carmeliet G, Kaufman JM, Fiers T, Huhtaniemi IT, Vanderschueren D, Claessens F. Sex hormone-binding globulin regulation of androgen bioactivity in vivo: validation of the free hormone hypothesis. Sci Rep. 2016;6:35539. PMID: 27748448

9. PROMETRIUM (progesterone, USP) Capsules. Prescribing Information. U.S. Food and Drug Administration, Drugs@FDA, Application No. NDA 020843.

Anastrozole in Men on TRT: What It Does, When It Helps, and When It Doesn’t

You started testosterone therapy hoping to feel sharper, stronger, and more like yourself. But a few weeks in, your doctor added another prescription to the mix—anastrozole—with a brief explanation about estrogen. Maybe your levels came back elevated. Maybe it was just standard protocol.

If you’ve ever wondered what anastrozole is actually doing, whether you need it, and what happens when it’s used too aggressively, this post is for you. The answers might surprise you—especially the part about gynecomastia.

Why Estrogen Matters in Men

Estrogen is not a female hormone. It’s a steroid hormone that men produce, require, and depend on for basic physiological function. In men, the primary form is estradiol (E2), produced largely through a conversion process called aromatization—testosterone is converted to estradiol by an enzyme called aromatase. More than 80% of circulating estradiol in men comes from this peripheral conversion.

Estradiol does a remarkable amount of work in the male body. It plays a central role in bone density, cardiovascular health, lipid regulation, cognition, mood, sleep quality, and libido. Estradiol is now understood to be the dominant regulator of bone resorption in men—not testosterone. Men with very low estradiol develop osteoporosis. Men with suppressed estradiol on TRT often report joint pain, low libido, depression, and brain fog—the same symptoms they were trying to fix with testosterone in the first place.

The problem isn’t estrogen itself. It’s estradiol that falls too low when aromatase is over-suppressed, or rises too high relative to testosterone. That balance—not any single number in isolation—is what matters clinically.

Estradiol isn’t the enemy on TRT. The relationship between testosterone and estradiol matters far more than either number read in isolation.

What Anastrozole Actually Does

Anastrozole is an aromatase inhibitor (AI). It blocks aromatase, the enzyme responsible for converting testosterone to estradiol. When aromatase activity is suppressed, less testosterone converts—and circulating estradiol drops.

It is FDA-approved for breast cancer treatment and prevention in postmenopausal women. Its use in men on TRT is entirely off-label, meaning it’s prescribed based on clinical reasoning rather than a specific indication in the drug’s labeling. That doesn’t make it inappropriate—off-label prescribing is standard in hormone medicine—but it does mean the prescriber bears responsibility for the clinical judgment behind each prescription.

Anastrozole is typically prescribed as a low-dose oral tablet in the TRT context, often 0.25 mg to 0.5 mg taken two to three times per week. The goal isn’t to eliminate estradiol. The goal is to keep testosterone and estradiol in a healthy relationship to each other—and that relationship looks different depending on where your testosterone level is optimized.

The Evidence on Estradiol and Sexual Function

One of the most important studies in this area was published in the New England Journal of Medicine in 2013. Finkelstein and colleagues enrolled 400 healthy men, suppressed their endogenous testosterone and estradiol, then randomized them to receive varying doses of testosterone—with or without an aromatase inhibitor to block estradiol conversion.

When estradiol was suppressed alongside testosterone, sexual function declined significantly—even in men who had adequate testosterone levels. Sexual desire and erectile function tracked with estradiol, not with testosterone alone. The conclusion was direct: estradiol plays an independent and essential role in male sexual function. A separate retrospective study further found that the estradiol-to-testosterone ratio independently predicted erectile function after controlling for other variables—reinforcing that the balance between these two hormones matters more than either value in isolation.

This matters directly for how anastrozole is used in practice. If an aromatase inhibitor is suppressing estradiol below the functional range, sexual function often declines—not improves. The drug intended to optimize TRT may be neutralizing its most meaningful benefit.

Why a Fixed Estradiol Target Misses the Point

For years, many TRT protocols aimed to keep estradiol within a fixed absolute range—often somewhere in the 20–40 pg/mL band. That target was derived from population reference ranges built around average men with average testosterone levels. It doesn’t hold when testosterone is optimized significantly higher.

The more clinically meaningful tool is the testosterone-to-estradiol ratio, or T:E2, calculated by dividing total testosterone in ng/dL by estradiol in pg/mL. Importantly, this ratio has two meaningful edges—a floor and a ceiling—and clinical problems arise at either end. A 2025 comprehensive review examining T:E2 data across multiple large population studies described a beneficial range of approximately 10 to 30. Below 10, estradiol is high relative to testosterone and estrogen-dominant symptoms—water retention, gynecomastia, reduced libido—become more likely. Above 30, estradiol is insufficient relative to testosterone and the low-estradiol picture emerges: joint pain, brain fog, poor sleep, reduced bone protection, and impaired sexual function.

A study in men with hypogonadotropic hypogonadism established a T:E2 ratio of 12 as a clinically meaningful lower threshold, below which erectile function was significantly impaired. But the lower bound only tells part of the story. A man with testosterone of 1,000 ng/dL and estradiol of 1 pg/mL has a T:E2 of 1,000—technically above that threshold, but clearly estradiol-deficient and symptomatic. The ratio only functions as a useful clinical tool when both edges of the range are respected.

Consider the math in an optimized TRT context: if testosterone is 2,000 ng/dL and estradiol is 20 pg/mL, the T:E2 ratio is 100—well above the upper bound of 30. That isn’t controlled estrogen; it’s estrogen deficiency in a high-androgen environment. The same estradiol of 20 pg/mL in a man with testosterone of 400 ng/dL produces a T:E2 of 20, which falls comfortably within the healthy range. Same estradiol number, opposite clinical meaning. This is why fixed absolute targets fail men on optimized TRT.

The T:E2 ratio has a floor and a ceiling. Most over-suppression errors on TRT are violations of the upper bound—not the lower one.

The Gynecomastia Paradox: How Suppressing Estrogen Can Cause What You’re Trying to Prevent

One of the most common reasons anastrozole is added to a TRT protocol is fear of gynecomastia—the development of glandular breast tissue in men. That concern is clinically legitimate. When estradiol rises significantly relative to testosterone, it can stimulate ductal proliferation in breast tissue, and no man starting TRT wants that outcome.

The clinical irony is that overly aggressive aromatase inhibition can promote both forms of breast enlargement men want to avoid—through a two-step pathway that runs through insulin resistance, ectopic fat deposition, and local aromatase activity in breast tissue.

Step One: Anastrozole, Insulin Resistance, and Ectopic Fat Redistribution

A double-blind randomized crossover study in healthy men found that six weeks of anastrozole therapy produced a statistically significant reduction in insulin sensitivity, measured by hyperinsulinemic-euglycemic clamp. The authors concluded that local estrogen production in skeletal muscle plays an important role in peripheral insulin sensitivity, and that aromatase inhibition disrupts this. The same study noted a reduction in leptin and raised the possibility of a shift from subcutaneous toward visceral fat deposition.

This is consistent with the Finkelstein 2013 New England Journal of Medicine data showing that estradiol—not testosterone—is the primary regulator of fat mass in men. When estradiol was suppressed in that trial, fat accumulation increased regardless of testosterone level.

When insulin resistance drives fat redistribution toward visceral and ectopic depots—including the chest wall and breast region—the result is pseudogynecomastia: breast enlargement from fat deposition rather than glandular proliferation. This is clinically distinct from true gynecomastia, produces the same unwanted cosmetic outcome, and does not respond to further anastrozole use.

Step Two: Ectopic Breast Fat as a Local Aromatase Source

Breast adipose tissue is not metabolically inert. It contains active aromatase and converts androgens to estrogens locally, generating an estrogen-rich microenvironment within breast tissue itself—independent of what circulating estradiol levels show on a blood draw.

The clinical literature on gynecomastia in obese men documents this pathway explicitly. Increased aromatase activity in adipose tissue, combined with leptin’s capacity to stimulate aromatase in breast tissue and directly promote epithelial cell growth, is recognized as a contributor to true glandular gynecomastia in overweight and obese men—not just pseudogynecomastia.

So the paradox closes: anastrozole prescribed to prevent gynecomastia promotes insulin resistance and ectopic fat redistribution toward the breast region—producing pseudogynecomastia—and that accumulated breast adipose tissue then becomes a local estradiol source capable of driving true glandular proliferation. The AI blocks circulating aromatase while inadvertently creating a new local aromatase depot in exactly the tissue it was meant to protect.

To be clear about the evidence: each mechanistic link in this sequence is supported by peer-reviewed data. The complete pathway from anastrozole use to glandular gynecomastia has not been studied as a direct clinical endpoint in TRT patients specifically. The inference is mechanistically coherent and grounded in the underlying biology—but should be understood as an evidence-informed argument rather than a proven causal chain in the TRT population.

The drug prescribed to prevent gynecomastia can promote the fat redistribution and local aromatase activity that drive both forms of breast enlargement it was meant to stop.

When Anastrozole Is Clinically Justified

There are men on TRT who genuinely benefit from anastrozole. This happens when estradiol rises high enough relative to testosterone to produce clear, confirmed symptoms—and when labs support that picture.

Symptoms That May Indicate Elevated Estradiol

Nipple tenderness or early glandular development is one of the more objective early signs that estradiol has risen significantly relative to testosterone. Gynecomastia that progresses to established glandular tissue can be permanent even after estradiol is corrected, so acting early matters. Water retention around the midsection and face, emotional lability, and difficulty with erections despite adequate testosterone levels are other symptoms that—in the context of a low T:E2 ratio on labs—constitute a reasonable clinical case for considering an AI.

What the Labs Should Show

Symptoms alone aren’t enough to justify starting an aromatase inhibitor. Estradiol should be measured using a sensitive assay—not a standard immunoassay, which is less accurate in men at lower estradiol ranges. Total and free testosterone should be drawn at the same time so the T:E2 ratio can be calculated in context. When the ratio falls below 10 in the presence of symptomatic estrogen excess, a clinical conversation about anastrozole is reasonable. Without both—symptoms and a ratio that warrants intervention—treating a number on a page is not good medicine.

When Anastrozole Does More Harm Than Good

Anastrozole is routinely co-prescribed with TRT in many practices as a preventive measure, regardless of symptoms or ratio. The reasoning is intuitive—more testosterone means more aromatization, so add an AI to stay ahead of it. In practice, this approach suppresses estradiol in men who didn’t need suppression in the first place, and sets in motion the metabolic cascade described above.

The symptoms of iatrogenic low estradiol look remarkably like the symptoms of low testosterone: joint pain and stiffness, low libido, poor sleep, mood changes, fatigue, and brain fog. Add the long-term risk of reduced bone density from sustained suppression, and the risk-benefit calculation for reflexive AI prescribing becomes difficult to justify.

The High Converter Who Doesn’t Need an AI

Some men convert testosterone to estradiol at higher rates due to body composition, genetics, and age. A man with higher adiposity may show estradiol well above typical reference ranges on TRT and feel completely well—because his T:E2 ratio is intact given his testosterone level. If he has no symptoms of estrogen excess and his ratio is in range, prescribing an aromatase inhibitor is intervening where no intervention was needed—and risks triggering the insulin resistance and fat redistribution cycle described above.

The more appropriate target in that scenario is body composition. Reducing adipose tissue reduces systemic aromatase activity and improves the ratio without pharmacologic suppression.

The Sensitivity Problem

Anastrozole’s effect on estradiol is not perfectly predictable. Individual responses vary significantly—some patients take a small dose and crash their estradiol, while others require higher doses for the same effect. Fixed-dose protocols prescribed reflexively carry real risk of producing iatrogenic estrogen deficiency that may take weeks to resolve and that looks, on labs and symptoms, indistinguishable from the problem you were trying to treat.

A Pattern Worth Recognizing

A patient came in having been on TRT for about eighteen months. Testosterone levels were well above 1,000 ng/dL, but the patient continued to report fatigue, joint stiffness, and a complete absence of the libido improvement that had initially prompted therapy. The protocol included anastrozole at 0.5 mg three times per week.

Estradiol came back at 8 pg/mL. T:E2 ratio: above 125—well beyond the upper bound of the healthy range. That’s not estrogen management; that’s estrogen deficiency created by the treatment itself. After discontinuing anastrozole and allowing estradiol to recover over several weeks, most of the persistent symptoms resolved. Testosterone hadn’t changed. What changed was giving estradiol room to do its job.

This pattern is not unusual. It’s the reason experienced hormone clinicians approach aromatase inhibitors with a strong preference for evidence-first prescribing: symptoms plus ratio-contextualized labs, not reflex prophylaxis.

Monitoring If You Are on Anastrozole

If anastrozole is part of your current protocol, monitoring should include sensitive estradiol and total and free testosterone drawn together so the T:E2 ratio can be tracked at each timepoint. Every three months while titrating; longer intervals once stable.

If you’re experiencing joint pain, low libido, mood changes, or fatigue on a protocol that includes an AI, low estradiol should be on the differential before assuming the testosterone dose needs to go up. Bone density is worth monitoring beyond one year of use, given estradiol’s dominant role in male skeletal maintenance.

What to Do If You’re Not Sure Your Protocol Is Right

If you’re on TRT and not feeling the way you expected to—especially if your protocol includes an aromatase inhibitor—a thorough review of your labs in the context of your symptoms is a reasonable first step. The right question isn’t whether your testosterone number is high enough. It’s whether your testosterone and estradiol are in the right relationship to each other, and whether what you’re taking is actually working for you or against you.

At Precision Hormone Consulting, this is exactly the kind of case we see regularly: patients who are technically on therapy but not benefiting from it, often because one variable in the protocol is undermining everything else. Getting it right requires time, attention, and a willingness to look at the full picture rather than manage individual numbers in isolation.

We offer a free initial consultation, available virtually throughout Texas and Arizona, or by calling the clinic at 832-281-5199. It’s a conversation, not a commitment—and it costs you nothing to find out whether something in your current plan deserves a closer look.

References

1. Finkelstein JS, Lee H, Burnett-Bowie SA, Pallais JC, Yu EW, Borges LF, et al. Gonadal steroids and body composition, strength, and sexual function in men. N Engl J Med. 2013;369(11):1011–1022. doi: 10.1056/NEJMoa1206168. PMID: 24024838.

2. Khosla S, Melton LJ 3rd, Riggs BL. Clinical review 144: estrogen and the male skeleton. J Clin Endocrinol Metab. 2002;87(4):1443–1450. PMID: 11932262.

3. Pan B, Ye H, Huang Y, et al. Relationship between penile erection and the ratio of estradiol to testosterone: A retrospective study. Andrologia. 2020;52(9):e13701. PMID: 32167186.

4. Seaman E, Bernstein A, Bhindi R, et al. A review on testosterone: estradiol ratio—does it matter, how do you measure it, and can you optimize it? World J Mens Health. 2025;43(3):458–471. doi: 10.5534/wjmh.240029.

5. Aydın A, Selvi I, Basar H. Role of testosterone to estradiol ratio in predicting the efficacy of recombinant human chorionic gonadotropin and testosterone treatment in male hypogonadism. Int Urol Nephrol. 2023;55(10):2603–2609. PMID: 37634764.

6. Gibb FW, Homer NZM, Faqehi AMM, et al. Aromatase inhibition reduces insulin sensitivity in healthy men. J Clin Endocrinol Metab. 2016;101(5):2040–2048. doi: 10.1210/jc.2015-4146. PMID: 26990060.

7. Grossmann M, Cheung AS, Lasaitiene D, et al. Adipose tissue dysfunction and obesity-related male hypogonadism. Clin Endocrinol (Oxf). 2022;97(1):11–21. PMID: 35446432.

8. Braunstein GD. Gynecomastia: etiology, diagnosis, and treatment. In: Feingold KR, et al., eds. Endotext. MDText.com; 2023. Available at: https://www.ncbi.nlm.nih.gov/books/NBK279105/

9. Johnson RE, Murad MH. Gynecomastia: pathophysiology, evaluation, and management. Mayo Clin Proc. 2009;84(11):1010–1015. PMID: 19880690.

Medical Disclaimer: This content is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Anastrozole is an FDA-approved medication used off-label in the context of testosterone replacement therapy. Individual clinical decisions should be made in consultation with a licensed physician who has reviewed your complete medical history and current laboratory values. Do not adjust or discontinue any prescribed medication without guidance from your treating provider.